.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Accenture
Argus Health
Cantor Fitzgerald
Julphar
Chinese Patent Office
Healthtrust
Daiichi Sankyo
Cipla
Federal Trade Commission

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040620

« Back to Dashboard
NDA 040620 describes METHYLPREDNISOLONE ACETATE, which is a drug marketed by Watson Labs, Akorn, Sandoz Inc, Teva Pharms Usa, and Sandoz, and is included in eleven NDAs. It is available from six suppliers. Additional details are available on the METHYLPREDNISOLONE ACETATE profile page.

The generic ingredient in METHYLPREDNISOLONE ACETATE is methylprednisolone acetate. There are thirty-nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the methylprednisolone acetate profile page.

Summary for NDA: 040620

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 040620

Suppliers and Packaging for NDA: 040620

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
METHYLPREDNISOLONE ACETATE
methylprednisolone acetate
INJECTABLE;INJECTION 040620 ANDA Teva Parenteral Medicines, Inc. 0703-0043 0703-0043-01 1 VIAL, MULTI-DOSE in 1 CARTON (0703-0043-01) > 5 mL in 1 VIAL, MULTI-DOSE
METHYLPREDNISOLONE ACETATE
methylprednisolone acetate
INJECTABLE;INJECTION 040620 ANDA Teva Parenteral Medicines, Inc. 0703-0045 0703-0045-01 1 VIAL, MULTI-DOSE in 1 CARTON (0703-0045-01) > 10 mL in 1 VIAL, MULTI-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength40MG/ML
Approval Date:Oct 27, 2006TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength80MG/ML
Approval Date:Oct 27, 2006TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Colorcon
Cerilliant
UBS
Baxter
Harvard Business School
Novartis
Mallinckrodt
Queensland Health
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot